These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 20652456)

  • 1. ¹⁸F-FAMT uptake correlates with tumor proliferative activity in oral squamous cell carcinoma: comparative study with ¹⁸F-FDG PET and immunohistochemistry.
    Miyashita G; Higuchi T; Oriuchi N; Arisaka Y; Hanaoka H; Tominaga H; Morita S; Miyakubo M; Ishikita T; Nakasone Y; Negishi A; Yokoo S; Endo K
    Ann Nucl Med; 2010 Oct; 24(8):579-84. PubMed ID: 20652456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of intratumoral inflammatory process on 18F-FDG uptake: pathologic and comparative study with 18F-fluoro-α-methyltyrosine PET/CT in oral squamous cell carcinoma.
    Kim M; Achmad A; Higuchi T; Arisaka Y; Yokoo H; Yokoo S; Tsushima Y
    J Nucl Med; 2015 Jan; 56(1):16-21. PubMed ID: 25476535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of ¹⁸F-α-methyl tyrosine PET/CT for the detection of bone marrow invasion in patients with oral squamous cell carcinoma: comparison with ¹⁸F-FDG PET/CT and MRI.
    Kim M; Higuchi T; Arisaka Y; Achmad A; Tokue A; Tominaga H; Miyashita G; Miyazaki H; Negishi A; Yokoo S; Tsushima Y
    Ann Nucl Med; 2013 Jun; 27(5):423-30. PubMed ID: 23436243
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic usefulness of ¹⁸F-FAMT PET and L-type amino acid transporter 1 (LAT1) expression in oral squamous cell carcinoma.
    Nobusawa A; Kim M; Kaira K; Miyashita G; Negishi A; Oriuchi N; Higuchi T; Tsushima Y; Kanai Y; Yokoo S; Oyama T
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1692-700. PubMed ID: 23801167
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Transport of 3-fluoro-L-α-methyl-tyrosine by tumor-upregulated L-type amino acid transporter 1: a cause of the tumor uptake in PET.
    Wiriyasermkul P; Nagamori S; Tominaga H; Oriuchi N; Kaira K; Nakao H; Kitashoji T; Ohgaki R; Tanaka H; Endou H; Endo K; Sakurai H; Kanai Y
    J Nucl Med; 2012 Aug; 53(8):1253-61. PubMed ID: 22743251
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Kim M; Higuchi T; Nakajima T; Andriana P; Hirasawa H; Tokue A; Kurihara J; Yokoo S; Tsushima Y
    Oral Radiol; 2019 Sep; 35(3):308-314. PubMed ID: 30778900
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Sato J; Kitagawa Y; Watanabe S; Asaka T; Ohga N; Hirata K; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2017 Sep; 124(3):261-270. PubMed ID: 28734696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. (18)F-FDG uptake on PET correlates with biological potential in early oral squamous cell carcinoma.
    Yokobori Y; Toyoda M; Sakakura K; Kaira K; Tsushima Y; Chikamatsu K
    Acta Otolaryngol; 2015 May; 135(5):494-9. PubMed ID: 25739639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Uptake of positron emission tomography tracers reflects the tumor immune status in esophageal squamous cell carcinoma.
    Kuriyama K; Higuchi T; Yokobori T; Saito H; Yoshida T; Hara K; Suzuki S; Sakai M; Sohda M; Higuchi T; Tsushima Y; Asao T; Kaira K; Kuwano H; Shirabe K; Saeki H
    Cancer Sci; 2020 Jun; 111(6):1969-1978. PubMed ID: 32302443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FDG-PET predicts survival and distant metastasis in oral squamous cell carcinoma.
    Suzuki H; Hasegawa Y; Terada A; Hyodo I; Nakashima T; Nishio M; Tamaki T
    Oral Oncol; 2009 Jul; 45(7):569-73. PubMed ID: 18804407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complementary roles of tumour specific PET tracer ¹⁸F-FAMT to ¹⁸F-FDG PET/CT for the assessment of bone metastasis.
    Morita M; Higuchi T; Achmad A; Tokue A; Arisaka Y; Tsushima Y
    Eur J Nucl Med Mol Imaging; 2013 Oct; 40(11):1672-81. PubMed ID: 24006150
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ¹⁸F-FAMT in patients with multiple myeloma: clinical utility compared to ¹⁸F-FDG.
    Isoda A; Higuchi T; Nakano S; Arisaka Y; Kaira K; Kamio T; Mawatari M; Matsumoto M; Sawamura M; Tsushima Y
    Ann Nucl Med; 2012 Dec; 26(10):811-6. PubMed ID: 22903817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor thickness, depth of invasion, and Bcl-2 expression are correlated with FDG-uptake in oral squamous cell carcinomas.
    Suzuki H; Fukuyama R; Hasegawa Y; Tamaki T; Nishio M; Nakashima T; Tatematsu M
    Oral Oncol; 2009 Oct; 45(10):891-7. PubMed ID: 19457711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biological significance of fluorine-18-α-methyltyrosine (FAMT) uptake on PET in patients with oesophageal cancer.
    Suzuki S; Kaira K; Ohshima Y; Ishioka NS; Sohda M; Yokobori T; Miyazaki T; Oriuchi N; Tominaga H; Kanai Y; Tsukamoto N; Asao T; Tsushima Y; Higuchi T; Oyama T; Kuwano H
    Br J Cancer; 2014 Apr; 110(8):1985-91. PubMed ID: 24667647
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-fluoromisonidazole PET uptake is correlated with hypoxia-inducible factor-1α expression in oral squamous cell carcinoma.
    Sato J; Kitagawa Y; Yamazaki Y; Hata H; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    J Nucl Med; 2013 Jul; 54(7):1060-5. PubMed ID: 23699668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Advantage of FMISO-PET over FDG-PET for predicting histological response to preoperative chemotherapy in patients with oral squamous cell carcinoma.
    Sato J; Kitagawa Y; Yamazaki Y; Hata H; Asaka T; Miyakoshi M; Okamoto S; Shiga T; Shindoh M; Kuge Y; Tamaki N
    Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2031-41. PubMed ID: 24867258
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretreatment primary tumor SUVmax measured by FDG-PET and pathologic tumor depth predict for poor outcomes in patients with oral cavity squamous cell carcinoma and pathologically positive lymph nodes.
    Liao CT; Chang JT; Wang HM; Ng SH; Hsueh C; Lee LY; Lin CH; Chen IH; Huang SF; Cheng AJ; See LC; Yen TC
    Int J Radiat Oncol Biol Phys; 2009 Mar; 73(3):764-71. PubMed ID: 18835509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SUVmax of FDG-PET correlates with the effects of neoadjuvant chemoradiotherapy for oral squamous cell carcinoma.
    Miyawaki A; Ikeda R; Hijioka H; Ishida T; Ushiyama M; Nozoe E; Nakamura N
    Oncol Rep; 2010 May; 23(5):1205-12. PubMed ID: 20372831
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation of metabolism/hypoxia markers and fluorodeoxyglucose uptake in oral squamous cell carcinomas.
    Yamada T; Uchida M; Kwang-Lee K; Kitamura N; Yoshimura T; Sasabe E; Yamamoto T
    Oral Surg Oral Med Oral Pathol Oral Radiol; 2012 Apr; 113(4):464-71. PubMed ID: 22676927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High 2-[18F]fluoro-2-deoxy-d-glucose (18FDG) uptake measured by positron emission tomography is associated with reduced overall survival in patients with oral squamous cell carcinoma.
    Hofele C; Freier K; Thiele OC; Haberkorn U; Buchmann I
    Oral Oncol; 2009 Nov; 45(11):963-7. PubMed ID: 19665923
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.